GlassScriptPhysician profile
Byron L Nelson
NPI 1487673299
$3,307.44
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,263 · 2020: $326 · 2021: $556 · 2022: $572 · 2023: $570 · 2024: $20.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $590.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $632.63 | 2019-2023 | |
| Abbvie INC. | $466.64 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $306.92 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $263.59 | 2019-2021 | |
| Glaxosmithkline, LLC. | $205.52 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.01 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $156.39 | 2022-2023 | |
| Amgen INC. | $118.47 | 2019-2023 | Otezla, Repatha |
| Lilly USA, LLC | $116.86 | 2019-2023 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $97.69 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.06 | 2019-2021 | |
| Dexcom, INC. | $90.05 | 2021-2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $89.65 | 2020 | |
| Merck Sharp & Dohme LLC | $77.50 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $57.87 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.04 | 2019 | |
| Genentech USA, INC. | $49.67 | 2019 | |
| Idorsia Pharmaceuticals US INC | $28.94 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $24.92 | 2023 | Rexulti |
| Ironshore Pharmaceuticals INC. | $24.73 | 2019 | |
| Exact Sciences Corporation | $24.58 | 2023 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $22.70 | 2023 | Gvoke Hypopen |
| Eisai INC. | $19.35 | 2022 | |
| Avanir Pharmaceuticals, INC. | $18.99 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $18.43 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.23 | 2021 | |
| Allegis Pharmaceuticals, LLC | $13.98 | 2022 | |
| Acadia Pharmaceuticals INC | $13.37 | 2019 | |
| Almatica Pharma LLC | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Byron Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.